Allylescaline

The existing entry's direct-listing observation and conditional analogue warning are supported, but its free-string Unscheduled label is normalized to canonicalStatus restricted_other because DEA says the lists are not comprehensive and the federal analogue test is unresolved without case-specific facts. The current federal sources establish no direct named scheduling for allylescaline, while DEA expressly warns that its lists are not comprehensive and that an unlisted substance may still be treated as a scheduled substance or regulated as a controlled-substance analogue. PubChem's exact identity record and the mescaline record show a shared substituted phenethylamine framework: allylescaline is 2-(3,5-dimethoxy-4-prop-2-enoxyphenyl)ethanamine, whereas mescaline is 2-(3,4,5-trimethoxyphenyl)ethanamine. That structural comparison supports analogue exposure as a plausible issue under 21 U.S.C. § 802(32), but the fetched primary sources do not adjudicate whether allylescaline satisfies the statutory substantial-similarity/effect or representation test in a particular prosecution. If treated as an analogue to the extent intended for human consumption, § 813 treats it as Schedule I for federal-law purposes. Section 841(a) prohibits knowing or intentional manufacture, distribution, dispensing or possession with intent to do so; § 841(b)(1)(C) supplies the Schedule I/II penalty ceiling of up to 20 years (up to 30 years after a prior felony drug conviction, with enhanced consequences where death or serious bodily injury results). Simple possession under § 844(a) carries up to 1 year and a minimum $1,000 fine for a first offense, with higher repeat-offense ranges; § 846 applies the same penalties to attempts and conspiracies. These are statutory ranges and do not resolve state law or case-specific analogue litigation.

The prior entry's statement that Allylescaline was a controlled substance effective 25 March 2015 is incomplete on both classification and effective date. MHLW's current designated-substances schedule identifies the exact Allylescaline chemical name and its salts as a designated substance; the designation notice gives an effective date of 4 April 2015. Allylescaline is not listed in the inspected current narcotics schedules (Narcotics and Psychotropics Control Act Appendix 1 or Cabinet Order Article 1) or either inspected psychotropics schedule. Under PMD Act Article 76-4, a designated substance may not be manufactured, imported, sold, transferred, possessed, purchased, received, or used for any purpose other than the Act's medical等用途 (medical diagnosis, treatment or prevention, and specified non-harmful uses). Accordingly, ordinary non-medical possession, use, supply, and import are prohibited; this is not a prescription-only classification. For a non-business violation, Article 84(28) provides up to three years' 拘禁刑 (拘禁刑; custodial sentence) or a fine up to ¥3,000,000, or both. Business manufacture, import, sale, transfer, or possession for sale/transfer (storage or display for that purpose) is separately covered by Article 83-9 and carries up to five years' 拘禁刑 or a fine up to ¥5,000,000, or both. These are statutory maximums.

The legacy wording is corrected to the canonical restricted_other status and official category spelling Verzeichnis e. The binding current consolidated BetmVV-EDI expressly names Allylescalin at item 148 in Annex 6. NIH PubChem independently identifies Allylescaline (CID 44719469, CAS 39201-75-7) as 2-(3,5-dimethoxy-4-prop-2-enoxyphenyl)ethanamine, the same connectivity as the Swiss designation; Swissmedic's official supplementary list supplies the freebase and hydrochloride CAS numbers and repeats the Swiss chemical designation. BetmVV-EDI Article 1(2) covers substances listed in Annexes 1–6 and specified salts, esters, ethers, carbamates, stereoisomers and preparations containing them, so the named freebase and covered salt forms must not be treated as unscheduled. BetmKV Article 3(2)(e) subjects Verzeichnis-e substances to Verzeichnis-a control measures, Article 5(2) assigns their operating permit to the EDI, and Article 11(1) requires an operating permit for handling activities including manufacture, obtaining, brokering, import/export, supply and trade. BetmG Article 7(1) requires EDI authorization and compliance with its conditions for cultivating, manufacturing, importing/exporting, storing, using or placing Article 7 materials/products into circulation; Article 20(1)(c) provides up to three years' imprisonment or a monetary penalty for specified unauthorized handling. The exact Verzeichnis-e listing supports controlled/restricted treatment, not a categorical Verzeichnis-d prohibition or an ordinary prescription/consumer route. Swissmedic cautions that its ancillary lists are not exhaustive and that only BetmVV-EDI schedules are binding. This is a research snapshot as of 28 August 2026, not legal advice.